However, treatment with the morin compound significantly decreased the expression levels of NLRP3 and ASC and significantly reduced the pro-caspase-1 (p50)/cleaved-caspase-1 (p20) ratio, thereby decreasing caspase-1 activation in LPS+ATP-stimulated NSCLC cells in a dose-dependent manner (p < 0.001) (Figure 9A,B, Supplementary Materials Figures S6 and S7). The gene discussed is CASP1; the disease is non-small cell lung carcinoma.